rheumatic autoimmune disease other than RA, or significant systemic involvement secondary to RA;

history of, or current, inflammatory joint disease other than RA, or other systemic autoimmune disorder;

diagnosis of RA before the age of 16;

bone/joint surgery within 12 weeks of study;

prior use of anti-TNF or other biologic therapy, an anti-alpha 4 integrin, or any cell-depleting therapies.

A Pharmacokinetic and Pharmacodynamic Study of MabThera (Rituximab) Plus Methotrexate in Patients With Rheumatoid Arthritis (RA)